Showing 1672 results
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™…
-
Press release /Basel, September 29, 2025 - Novartis today announced that Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender…
-
Story /The molecule restores the activity of neurons and neural circuits in a model of the disease.
-
Story /A conversation with Novartis Chief Digital Officer Bertrand Bodson
-
Story /Novartis is collaborating with Microsoft to apply machine learning to medicinal chemistry — part of an effort to leverage AI to bring treatments to patients more efficiently.
-
Press release /Phase III NETTER-2 trial met primary endpoint of improvement in progression-free survival (PFS) and key secondary endpoint of objective response rate (ORR) in patients with Grade 2 and 3 advanced…